James Paul Kastenmayer - Aug 23, 2022 Form 3 Insider Report for Aeglea BioTherapeutics, Inc. (AGLE)

Role
Interim CEO & General Counsel
Signature
/s/ James Kastenmayer
Stock symbol
AGLE
Transactions as of
Aug 23, 2022
Transactions value $
$0
Form type
3
Date filed
8/25/2022, 07:37 PM
Next filing
Feb 24, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding AGLE Common Stock 4K Aug 23, 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding AGLE Employee Stock Option (right to buy) Aug 23, 2022 Common Stock 130K $7.03 Direct F1
holding AGLE Employee Stock Option (right to buy) Aug 23, 2022 Common Stock 85K $3.17 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The options will vest as to 1/4th of the total shares on July 6, 2022, and then 1/48th of the shares will vest monthly thereafter, such that the option is fully vested on July 6, 2025, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F2 The stock option vests and becomes exercisable in 48 equal monthly installments beginning on March 17, 2022, until such time as the option is 100% vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.